Changes in anti-müllerian hormone levels as a biomarker for ovarian reserve after ultrasound-guided high-intensity focused ultrasound treatment of adenomyosis and uterine fibroid

J. S. Lee, G. Y. Hong, K. H. Lee, T. E. Kim

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Objective: To assess the changes in antimüllerian hormone (AMH) levels after ablation for symptomatic uterine fibroids and adenomyosis using ultrasound-guided high-intensity focused ultrasound (USgHIFU). Design: A prospective study. Setting: Gynaecological department in multiple hospitals in South Korea. Population: Patients with uterus fibroids and adenomyosis. Methods: Seventy-nine women with symptomatic uterine fibroids and adenomyosis who met the inclusion criteria were enrolled in our study between January 2014 and December 2014. All patients underwent USgHIFU ablations. Each patient was examined before and after treatment, and at 6 and 12 months after treatment by T2-weighted MRI imaging (T2WI) and T1-weighted MRI imaging (T1WI) with gadolinium injection. Symptom severity scores (SSS), Uterine Fibroid Symptom Quality of Life (UFS-QOL) questionnaire subscales, and reductions of treated volume were assessed. AMH levels before and 6 months after HIFU ablation were compared to determine whether USgHIFU ablation affected ovarian reserve. Main outcome measures: HIFU treatment did not affect the ovarian function. Results: HIFU treatment time (mean ± standard deviation), HIFU ablation time, and treatment energy were 73.5 ± 25.6 minutes, 9994.7 ± 386.8 seconds, and 364 713.8 ± 156 350.7 Joules, respectively. AMH levels before and 6 months after HIFU ablation were 2.11 ± 2.66 and 1.84 ± 2.57 μg/l, respectively. There was no significant difference in AMH level between the two time points (P > 0.05). Conclusions: USgHIFU ablation for uterine fibroid and adenomyosis was effective without affecting ovarian reserve. Tweetable abstract: HIFU ablation is a safe and effective treatment for patients with uterine fibroids and adenomyosis that does not affect ovarian function.

Original languageEnglish
Pages (from-to)18-22
Number of pages5
JournalBJOG: An International Journal of Obstetrics and Gynaecology
Volume124
DOIs
StatePublished - 1 Aug 2017

Fingerprint

Adenomyosis
Leiomyoma
High-Intensity Focused Ultrasound Ablation
Biomarkers
Hormones
Therapeutics
Republic of Korea
Gadolinium
Ovarian Reserve
Quality of Life
Outcome Assessment (Health Care)
Prospective Studies
Injections
Population

Keywords

  • Adenomyosis
  • HIFU
  • antimüllerian hormone
  • ovarian reserve
  • uterine fibroid

Cite this

@article{58baa0b99a8a455595f92f869aa31a47,
title = "Changes in anti-m{\"u}llerian hormone levels as a biomarker for ovarian reserve after ultrasound-guided high-intensity focused ultrasound treatment of adenomyosis and uterine fibroid",
abstract = "Objective: To assess the changes in antim{\"u}llerian hormone (AMH) levels after ablation for symptomatic uterine fibroids and adenomyosis using ultrasound-guided high-intensity focused ultrasound (USgHIFU). Design: A prospective study. Setting: Gynaecological department in multiple hospitals in South Korea. Population: Patients with uterus fibroids and adenomyosis. Methods: Seventy-nine women with symptomatic uterine fibroids and adenomyosis who met the inclusion criteria were enrolled in our study between January 2014 and December 2014. All patients underwent USgHIFU ablations. Each patient was examined before and after treatment, and at 6 and 12 months after treatment by T2-weighted MRI imaging (T2WI) and T1-weighted MRI imaging (T1WI) with gadolinium injection. Symptom severity scores (SSS), Uterine Fibroid Symptom Quality of Life (UFS-QOL) questionnaire subscales, and reductions of treated volume were assessed. AMH levels before and 6 months after HIFU ablation were compared to determine whether USgHIFU ablation affected ovarian reserve. Main outcome measures: HIFU treatment did not affect the ovarian function. Results: HIFU treatment time (mean ± standard deviation), HIFU ablation time, and treatment energy were 73.5 ± 25.6 minutes, 9994.7 ± 386.8 seconds, and 364 713.8 ± 156 350.7 Joules, respectively. AMH levels before and 6 months after HIFU ablation were 2.11 ± 2.66 and 1.84 ± 2.57 μg/l, respectively. There was no significant difference in AMH level between the two time points (P > 0.05). Conclusions: USgHIFU ablation for uterine fibroid and adenomyosis was effective without affecting ovarian reserve. Tweetable abstract: HIFU ablation is a safe and effective treatment for patients with uterine fibroids and adenomyosis that does not affect ovarian function.",
keywords = "Adenomyosis, HIFU, antim{\"u}llerian hormone, ovarian reserve, uterine fibroid",
author = "Lee, {J. S.} and Hong, {G. Y.} and Lee, {K. H.} and Kim, {T. E.}",
year = "2017",
month = "8",
day = "1",
doi = "10.1111/1471-0528.14739",
language = "English",
volume = "124",
pages = "18--22",
journal = "BJOG: An International Journal of Obstetrics and Gynaecology",
issn = "1470-0328",
publisher = "Wiley-Blackwell Publishing Ltd",

}

TY - JOUR

T1 - Changes in anti-müllerian hormone levels as a biomarker for ovarian reserve after ultrasound-guided high-intensity focused ultrasound treatment of adenomyosis and uterine fibroid

AU - Lee, J. S.

AU - Hong, G. Y.

AU - Lee, K. H.

AU - Kim, T. E.

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Objective: To assess the changes in antimüllerian hormone (AMH) levels after ablation for symptomatic uterine fibroids and adenomyosis using ultrasound-guided high-intensity focused ultrasound (USgHIFU). Design: A prospective study. Setting: Gynaecological department in multiple hospitals in South Korea. Population: Patients with uterus fibroids and adenomyosis. Methods: Seventy-nine women with symptomatic uterine fibroids and adenomyosis who met the inclusion criteria were enrolled in our study between January 2014 and December 2014. All patients underwent USgHIFU ablations. Each patient was examined before and after treatment, and at 6 and 12 months after treatment by T2-weighted MRI imaging (T2WI) and T1-weighted MRI imaging (T1WI) with gadolinium injection. Symptom severity scores (SSS), Uterine Fibroid Symptom Quality of Life (UFS-QOL) questionnaire subscales, and reductions of treated volume were assessed. AMH levels before and 6 months after HIFU ablation were compared to determine whether USgHIFU ablation affected ovarian reserve. Main outcome measures: HIFU treatment did not affect the ovarian function. Results: HIFU treatment time (mean ± standard deviation), HIFU ablation time, and treatment energy were 73.5 ± 25.6 minutes, 9994.7 ± 386.8 seconds, and 364 713.8 ± 156 350.7 Joules, respectively. AMH levels before and 6 months after HIFU ablation were 2.11 ± 2.66 and 1.84 ± 2.57 μg/l, respectively. There was no significant difference in AMH level between the two time points (P > 0.05). Conclusions: USgHIFU ablation for uterine fibroid and adenomyosis was effective without affecting ovarian reserve. Tweetable abstract: HIFU ablation is a safe and effective treatment for patients with uterine fibroids and adenomyosis that does not affect ovarian function.

AB - Objective: To assess the changes in antimüllerian hormone (AMH) levels after ablation for symptomatic uterine fibroids and adenomyosis using ultrasound-guided high-intensity focused ultrasound (USgHIFU). Design: A prospective study. Setting: Gynaecological department in multiple hospitals in South Korea. Population: Patients with uterus fibroids and adenomyosis. Methods: Seventy-nine women with symptomatic uterine fibroids and adenomyosis who met the inclusion criteria were enrolled in our study between January 2014 and December 2014. All patients underwent USgHIFU ablations. Each patient was examined before and after treatment, and at 6 and 12 months after treatment by T2-weighted MRI imaging (T2WI) and T1-weighted MRI imaging (T1WI) with gadolinium injection. Symptom severity scores (SSS), Uterine Fibroid Symptom Quality of Life (UFS-QOL) questionnaire subscales, and reductions of treated volume were assessed. AMH levels before and 6 months after HIFU ablation were compared to determine whether USgHIFU ablation affected ovarian reserve. Main outcome measures: HIFU treatment did not affect the ovarian function. Results: HIFU treatment time (mean ± standard deviation), HIFU ablation time, and treatment energy were 73.5 ± 25.6 minutes, 9994.7 ± 386.8 seconds, and 364 713.8 ± 156 350.7 Joules, respectively. AMH levels before and 6 months after HIFU ablation were 2.11 ± 2.66 and 1.84 ± 2.57 μg/l, respectively. There was no significant difference in AMH level between the two time points (P > 0.05). Conclusions: USgHIFU ablation for uterine fibroid and adenomyosis was effective without affecting ovarian reserve. Tweetable abstract: HIFU ablation is a safe and effective treatment for patients with uterine fibroids and adenomyosis that does not affect ovarian function.

KW - Adenomyosis

KW - HIFU

KW - antimüllerian hormone

KW - ovarian reserve

KW - uterine fibroid

UR - http://www.scopus.com/inward/record.url?scp=85028538542&partnerID=8YFLogxK

U2 - 10.1111/1471-0528.14739

DO - 10.1111/1471-0528.14739

M3 - Article

C2 - 28856867

AN - SCOPUS:85028538542

VL - 124

SP - 18

EP - 22

JO - BJOG: An International Journal of Obstetrics and Gynaecology

JF - BJOG: An International Journal of Obstetrics and Gynaecology

SN - 1470-0328

ER -